Fulgent Genetics Inc FLGT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if FLGT is a good fit for your portfolio.
News
-
Fulgent to Announce Second Quarter 2024 Financial Results on Friday, August 2, 2024
-
Fulgent Data at ASCO 2024 Highlights Antitumor Activity from Lead Therapeutic Oncology Candidate, FID-007, in Head and Neck Cancer
-
Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual Meeting
-
Moffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer Therapeutics
-
Fulgent Reports First Quarter 2024 Financial Results
Trading Information
- Previous Close Price
- $21.82
- Day Range
- $21.56–22.53
- 52-Week Range
- $18.91–44.09
- Bid/Ask
- $20.40 / $24.00
- Market Cap
- $668.51 Mil
- Volume/Avg
- 52 / 178,802
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.32
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 3.75%
Company Profile
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Value
- Total Number of Employees
- 1,012
- Website
- https://www.fulgentgenetics.com
Comparables
Valuation
|
Metric
|
FLGT
|
TIHE
|
VCYT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 189.41 |
Price/Book Value | 0.59 | — | 1.60 |
Price/Sales | 2.32 | — | 4.58 |
Price/Cash Flow | 22.50 | — | 31.88 |
Price/Earnings
FLGT
TIHE
VCYT
Financial Strength
|
Metric
|
FLGT
|
TIHE
|
VCYT
|
|---|---|---|---|
Quick Ratio | 4.81 | — | 4.41 |
Current Ratio | 5.09 | — | 5.00 |
Interest Coverage | −3,451.87 | — | −11,324.57 |
Quick Ratio
FLGT
TIHE
VCYT
Profitability
|
Metric
|
FLGT
|
TIHE
|
VCYT
|
|---|---|---|---|
Return on Assets (Normalized) | −0.46% | — | 8.19% |
Return on Equity (Normalized) | −0.50% | — | 8.76% |
Return on Invested Capital (Normalized) | −1.73% | — | 7.87% |
Return on Assets
FLGT
TIHE
VCYT
Diagnostics & Research Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| Kvxwczps | Gylc | $208.6 Bil | |||
| Danaher Corp
DHR
| Lmyvpnndpv | Nfvvtwk | $185.8 Bil | |||
| IQVIA Holdings Inc
IQV
| Gcbdsrjkk | Rdbdw | $44.7 Bil | |||
| IDEXX Laboratories Inc
IDXX
| Nnzqbvdnf | Pygbpm | $39.3 Bil | |||
| Agilent Technologies Inc
A
| Gpfbhzfpjb | Xdvq | $38.9 Bil | |||
| Mettler-Toledo International Inc
MTD
| Vxfmsdzzgh | Hbvzk | $29.3 Bil | |||
| Icon PLC
ICLR
| Ypqgthv | Kvcxxmp | $28.1 Bil | |||
| Illumina Inc
ILMN
| Fqztccns | Fdgjrjk | $18.7 Bil | |||
| Waters Corp
WAT
| Wxfdqdfm | Fwvs | $18.2 Bil | |||
| Labcorp Holdings Inc
LH
| Txqkrmyylf | Cjpkjpk | $18.1 Bil |